Mark Rolfe
Bristol-Myers Squibb (United States) · 121 works · 10,293 citations · h-index 34
Top works
- Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27
- A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- Drug discovery in the ubiquitin–proteasome system
- Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP).
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- Targeted Therapies for Cancer 2004
- Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma
- Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells
- The ubiquitin-mediated proteolytic pathway as a therapeutic area
- Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis
- SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
- Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
- Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
- Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors
- Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
- CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells
- Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
- Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)